SOPHiA GENETICS is a Swiss data-driven medicine company that develops and commercializes the SOPHiA DDM Platform, a cloud-native SaaS platform for analyzing complex multimodal healthcare data using artificial intelligence and machine learning. The platform enables healthcare providers, clinical laboratories, and biopharmaceutical companies to interpret genomic and radiomic data for oncology, hereditary cancers, rare diseases, and precision medicine research. The company's solutions are used globally for diagnostic and clinical decision support in genomics, with applications in cancer diagnosis, rare inherited disorders, and biomarker discovery.
SOPHiA GENETICS is publicly traded
IPO'd on July 27, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under SOPH.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2011
Employees
400–430
Total Funding
$230.8M
5 rounds
Total raised $230.8M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series F
Date
October 2020
Amount
$110M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| October 2020 | Series F | $110M | — | aMoon, Hitachi Ventures |
| October 2019 | Series E | $77M | — | Generation Investment Management |
| September 13, 2017 | Series D | $30M | — | Balderton Capital |
Jurgi Camblong
Co-Founder and Executive Chairman (transitioning July 2026)
Ross Muken
Chief Executive Officer (effective July 1, 2026)
Pierre Hutter
Co-Founder and Chief Scientific Officer
George Cardoza
Chief Financial Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Guardant Health
Oncology and precision diagnostics company offering comprehensive cancer sequencing and monitoring solutions.
Tempus AI
AI-driven precision oncology company offering real-world data analytics and clinical decision support for cancer diagnosis and treatment.
Veracyte
Molecular diagnostics company providing AI-powered genomic tests for cancer, thyroid, and lung disease diagnosis.
GeneDx
Genetic testing company offering comprehensive genomic testing for rare and inherited diseases.
Invitae
Medical genetics company providing genetic testing and analysis for rare diseases, oncology, and carrier screening.
Illumina
Leading sequencing technology and genomics analysis company providing sequencing instruments and bioinformatics solutions.
Yes, SOPHiA GENETICS is publicly traded under the ticker symbol SOPH on the NASDAQ. The company went public in July 27, 2021.
SOPHiA GENETICS trades under the ticker symbol SOPH on the NASDAQ. It began trading in July 27, 2021.
SOPHiA GENETICS (SOPH on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker SOPH to place an order.
SOPHiA GENETICS went public in July 27, 2021 via ipo. SOPHiA GENETICS completed its initial public offering on July 27, 2021, listing on NASDAQ under the ticker symbol SOPH. The company raised $234 million at $18 per share, with 13 million ordinary shares issued. Trading commenced on July 23, 2021.
SOPHiA GENETICS raised $230.8M across 5 disclosed funding rounds prior to its public listing.
SOPHiA GENETICS was co-founded by Jurgi Camblong, and Pierre Hutter in 2011.
SOPHiA GENETICS is headquartered in Rolle, Switzerland.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.